Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
CYP Oxidoreductase (Por) is the essential electron donor for all CYP enzymes and is responsible for the activation of CYP. The Taconic Hepatic CYP Reductase Null (HRN) mouse model possesses a targeted mutation that results in liver-specific deletion of the Por gene thereby resulting in a disruption of CYP metabolism in the liver. The objectives of these studies were to further characterize the HRN mouse using probe drugs metabolized by CYP. In addition, tumor exposure in xenograft tumor bearing HRN immune-compromised (nude) mice was also determined. In HRN mice following intravenous (iv) administration of midazolam, clearance (CL) was reduced by ∼ 80% compared to wild-type mice (WT). After oral administration, the AUC of midazolam was increased by ∼ 20-fold in HRN mice compared to WT mice; this greater effect suggests that hepatic first pass plays a role in the oral CL of midazolam. A 50% and an 80% decrease in CL were also observed in HRN mice following iv administration of docetaxel and theophylline, respectively, compared to WT mice. In addition, a 2- to 3-fold increase in tumor concentrations of G4222, a tool compound, were observed in tumor bearing HRN nude mice compared to tumor bearing nude WT mice. The observations from these experiments demonstrate that, for compounds that are extensively metabolized by hepatic CYP, the HRN mouse model could potentially be valuable for evaluating in vivo efficacy of tool compounds in drug discovery where high hepatic CL and low exposure may prevent in vivo evaluation of a new chemical entity.
Department of Drug Metabolism and Pharmacokinetics, ‡Cell Signaling Pathways and Translational Oncology, and §Non-clinical Operations, Genentech Inc. , South San Francisco, California, 94080, United States.
Jason W
JW
Boggs
Cornelis E C A
CE
Hop
Erin
E
McNamara
Yuzhong
Y
Deng
Kirsten
K
Messick
Kristina
K
West
Edna F
EF
Choo
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D000077143:Docetaxel; D055808:Drug Discovery; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000378:metabolism*; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics; D008099:Liver / Q000201:enzymology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008819:Mice, Nude; D008874:Midazolam / Q000493:pharmacokinetics*; D009251:NADPH-Ferrihemoprotein Reductase / Q000502:physiology*; D043823:Taxoids / Q000493:pharmacokinetics; D013806:Theophylline / Q000493:pharmacokinetics; D014665:Vasodilator Agents / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D006993:Hypnotics and Sedatives; D043823:Taxoids; D014665:Vasodilator Agents; D000077143:Docetaxel; D003577:Cytochrome P-450 Enzyme System; D013806:Theophylline; D009251:NADPH-Ferrihemoprotein Reductase; D008874:Midazolam
CYP reductase; mouse model; pharmacokinetics